Artes Medical
This article was originally published in The Gray Sheet
Executive Summary
ArteFill PMMA microsphere dermal filler premarket approval timeframe is pushed back to mid-2005 from the end of 2004. The firm's Dec. 1 release condemns reports of unlicensed use of the previous-generation filler Artecoll, currently marketed in Europe. San Diego-based Artes received an "approvable" letter in January, but final approval has hinged on construction and FDA inspection of a BSE-safe manufacturing facility for the bovine-based collagen product, which the firm claims treats wrinkles "permanently" (1"The Gray Sheet" Jan. 19, 2004, p. 5)...
You may also be interested in...
Collagen Implant PMA “Approvable” Letter Facilitates 2004 Launch – Artes
Artes Medical maintains that within six months FDA will inspect a collagen manufacturing facility under development, permitting U.S. launch of facial wrinkle treatment Artefill later this year
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.